Unregistered Sales of Equity Securities and Use of Proceeds (dollars and shares in millions, except per share data)
−Removed: The following table sets forth information with respect to purchases of shares of the Company’s common stock based on settled trades made during the three months ended June 30, 2022, by or on behalf of the Company:
+Added: The following table sets forth information with respect to purchases of shares of the Company’s common stock based on settled trades made during the three months ended September 30, 2022, by or on behalf of the Company:
Total Number of Shares Repurchased Average Price Paid Per Share Total Number of Shares Repurchased as Part of Publicly Announced Program Maximum Dollar Value of Shares that May Yet Be Repurchased Under the Program
−Removed: April 1 - April 30 (1)
−Removed: 0.2 275.51 0.2 1,631.5
−Removed: May 1 - May 31 0.5 247.54 0.5 1,516.1
−Removed: June 1 - June 30 1.2 234.13 1.2 1,231.5
+Added: July 1 - July 31 0.7 243.49 0.7 1,051.5
+Added: August 1 - August 31 0.4 256.17 0.4 931.5
+Added: September 1 - September 30 0.4 229.32 0.4 831.5
1.5 $ 243.35 1.5 $ 831.5
−Removed: (1) During the fourth quarter of 2021, the Company entered into an ASR program.
−Removed: At inception, the Company paid $1,000.0 and received 2.7 shares based on a calculation using 80% of the shares calculated at the price at the inception of agreements with two different banks, Goldman Sachs and Barclays.
−Removed: In March 2022, the Company received 0.6 shares of its common stock, arising from a partial acceleration with Barclays and a final settlement from Goldman Sachs, based on the average daily volume weighted average price per share of $277.40.
−Removed: On April 1, 2022, the Company received 0.2 shares of its common stock for final settlement from Barclays based on the average volume-weighted average price per share of $275.51.
−Removed: As of June 30, 2022, the Company had outstanding authorization from the board of directors to purchase up to $1,231.5 of the Company's common stock.
+Added: As of September 30, 2022, the Company had outstanding authorization from the board of directors to purchase up to $831.5 of the Company's common stock.
The repurchase authorization has no expiration date.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.